Data from EMA (European Medicines Agency) - Curated by EPG Health - Last updated 16 April 2018
Indication(s)
Treatment of adult patients with moderate to severe Alzheimer’s disease.
Learning Zones
An epgonline.org Learning Zone (LZ) is an area of the site dedicated to providing detailed self-directed medical education about a disease, condition or procedure.
Migraine Knowledge Centre
The Migraine Knowledge Centre features latest research on the prevalence and impact of migraine, the proposed neurological basis of the condition (and how this is being translated into new and exciting drug therapies), as well as current patient care strategies collated from headache organisations worldwide.
Acute and Advanced Heart Failure
What are the most effective treatments for acute heart failure? Can you define advanced heart failure? Discover here...
+ 3 more
Fabry Disease
Explore the pathophysiology and treatment options for Fabry disease, a deficiency of the lysosomal enzyme alpha-galactosidase A
Hyperammonaemia
Hyperammonaemia can result in serious neurological damage or death. Could you recognise the signs and symptoms?
+ 2 more
Cushing's Syndrome
Cushing’s syndrome shares symptoms such as hypertension, glucose intolerance and obesity with other common conditions – how can you confidently diagnose this rare disorder?
+ 2 more
Allergic Rhinitis
Allergic rhinitis causes great strain on the workforce. Help to reduce sick days and improve productivity with appropriate treatment options.
+ 4 more
ALP Lab Assessment
Discover and overview of hypophosphatasia and details required to facilitate the timely and accurate detection of low alkaline phosphatase.
Related Content
ACT-ICU Study: Activity and Cognitive Therapy in the Intensive Care Unit
Intensive care unit (ICU) hospitalization saves lives but often does so at a high personal cost to ICU survivors who frequently experience significant cognitive impairment and an array of physical and functional...
Added 1 year ago
ExAblate Transcranial MR Guided Focused Ultrasound for the Treatment of Parkinson's Disease
This is a feasibility study to evaluate the safety and initial effectiveness of unilateral ExAblate thermal ablation of the Vim thalamic nucleus of subjects suffering from medication-refractory, idiopathic, tremor-dominant PD, using the ExAblate...
Added 3 months ago
Subthalamotomy by ExAblate Transcranial System to Treat Motor Features of Parkinson's Disease
Based on published animal and human studies, ExAblate Transcranial subthalamotomy can be as safe and as effective as any of the surgical treatments within the currently accepted standard of care including radiofrequency...
Added 3 months ago
Prove of Concept Study, to Evaluate the Efficacy, Safety, and Tolerability of IBEROGAST in the Treatment of Bowel Troubles in Patients With Parkinson's Disease (PHYTOPARK)
The main objective of this study is to evaluate the efficacy of STW5 Iberogast, over a 28-day period, for the...
Added 3 years ago
Conservative Iron Chelation as a Disease-modifying Strategy in Parkinson's Disease (FAIRPARKII)
This study evaluates the effect of iron chelation as a therapeutic strategy to slow the progression of Parkinson's disease. Half...
Added 3 years ago
Depletion of adult neurogenesis exacerbates cognitive deficits in Alzheimer's disease by compromising hippocampal inhibition.
Background: The molecular mechanism underlying progressive memory loss in Alzheimer's disease is poorly understood. Neurogenesis in the adult hippocampus is a dynamic process that continuously changes the dentate gyrus...
Added 3 months ago
Apolipoprotein E Genotype and Sex Risk Factors for Alzheimer Disease: A Meta-analysis.
Objective: To determine how sex and apolipoprotein E (APOE) genotype affect the risks for developing mild cognitive impairment (MCI) and AD.
Added 3 months ago
Interpreting Biomarker Results in Individual Patients With Mild Cognitive Impairment in the Alzheimer's Biomarkers in Daily Practice (ABIDE) Project.
Objective: To construct biomarker-based prognostic models that enable determination of future AD dementia in patients with mild cognitive impairment (MCI).
Added 3 months ago
Amyloid-β and tau complexity - towards improved biomarkers and targeted therapies.
Most neurodegenerative diseases are proteinopathies, which are characterized by the aggregation of misfolded proteins. Although many proteins have an intrinsic propensity to aggregate, particularly when...
Added 3 months ago
Kv1.3 inhibition as a potential microglia-targeted therapy for Alzheimer's disease: preclinical proof of concept.
Microglia significantly contribute to the pathophysiology of Alzheimer's disease but an effective microglia-targeted therapeutic approach is not yet available clinically. The potassium channels Kv1.3 and Kir2.1 play important...
Added 3 months ago
World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Biological Treatment of Alzheimer ’s disease and other dementias
Like with the preceding guidelines of this series (Bauer et al. 2002, Bandelow et al. 2008b), these practice guidelines for...
Added 7 years ago
EFNS guidelines for the diagnosis and management of Alzheimer's disease
The aim of this revised international guideline was to present a peer-reviewed evidence-based statement for the guidance of practice for clinical neurologists, geriatricians, psychiatrists, and other specialist physicians responsible for the care...
Added 8 years ago
Clinical practice with anti-dementia drugs: A revised (third) consensus statement from the British Association for Psychopharmacology
The British Association for Psychopharmacology coordinated a meeting of experts to review and revise its previous 2011 guidelines for clinical practice with anti-dementia drugs.
Added 7 years ago
More information
Category | Value |
---|---|
Agency product number | EMEA/H/C/002658 |
Orphan designation | No |
Date First Approved | 29-04-2013 |
Type | Medicinal product subject to restricted medical prescription |
Marketing authorisation holder | KRKA, d.d. |